In silico tools to aid medicinal chemistry: optimising bromodomain inhibitors

In silico tools to aid medicinal chemistry: optimising bromodomain inhibitors

<p>Development of ligands for bromodomains has expanded our understanding of gene regulation and epigenetic links to disease. These acetylated lysine ‘reader’ domains are found within larger macromolecules that are involved in gene transcription and degradation. This thesis looks to employ...

Descrizione completa

Dettagli Bibliografici
Autore principale:	Bluck, J
Altri autori:	Biggin, P
Natura:	Tesi
Pubblicazione:	2019

Documenti analoghi

Epigenetic mechanisms in silico: understanding demethylation and rational design of bromodomain inhibitors
di: Coelho, W
Pubblicazione: (2017)

Development of small molecule CREBBP bromodomain ligands using medicinal chemistry-based approaches
di: Moroglu, M
Pubblicazione: (2020)

Emerging tools to investigate bromodomain functions
di: Kougnassoukou Tchara, P, et al.
Pubblicazione: (2019)

Developing inhibitors of bromodomain-histone interactions
di: Hewings, D
Pubblicazione: (2014)

Small-molecule bromodomain inhibitors for cancer therapy
di: Qi, J, et al.
Pubblicazione: (2010)

BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability
di: Jennings, L, et al.
Pubblicazione: (2018)

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
di: Ciceri, P, et al.
Pubblicazione: (2014)

Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
di: Ferguson, F, et al.
Pubblicazione: (2013)

Chemical probes and inhibitors of bromodomains outside the BET family
di: Moustakim, M, et al.
Pubblicazione: (2016)

Developing small molecule inhibitors of bromodomain-histone interactions
di: Wilson, B, et al.
Pubblicazione: (2015)

Development of small molecule inhibitors of the bromodomain-histone interaction
di: Rooney, TPC
Pubblicazione: (2014)

Discovery of BET bromodomain inhibitors and their role in target validation
di: Mueller, S, et al.
Pubblicazione: (2014)

Bromodomain Protein Inhibitors Reorganize the Chromatin of Synovial Fibroblasts
di: Monika Krošel, et al.
Pubblicazione: (2023-04-01)

Bromodomain inhibitors and cancer therapy: From structures to applications
di: Montserrat Pérez-Salvia, et al.
Pubblicazione: (2017-05-01)

Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma
di: Wei Meng, et al.
Pubblicazione: (2018-10-01)

Pyronaridine as a Bromodomain-Containing Protein 4-<i>N</i>-Terminal Bromodomain (BRD4-BD1) Inhibitor: <i>In Silico</i> Database Mining, Molecular Docking, and Molecular Dynamics Simulation
di: Mahmoud A. A. Ibrahim, et al.
Pubblicazione: (2023-07-01)

Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery.
di: Philpott, M, et al.
Pubblicazione: (2011)

Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery.
di: Philpott, M, et al.
Pubblicazione: (2011)

Corrigendum: Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
di: Ciceri, P, et al.
Pubblicazione: (2014)

Chemical Space Expansion of Bromodomain Ligands Guided by in Silico Virtual Couplings (AutoCouple)
di: Laurent Batiste, et al.
Pubblicazione: (2018-02-01)

Development of selective CBP/P300 benzoxazepine bromodomain inhibitors
di: Popp, T, et al.
Pubblicazione: (2016)

Developing small molecule inhibitors of the CREBBP bromodomain-histone interaction
di: Rooney, T, et al.
Pubblicazione: (2012)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
di: Kenneth K. W. To, et al.
Pubblicazione: (2023-03-01)

Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off?
di: Ian J. Groves, et al.
Pubblicazione: (2020-07-01)

Optimisation of Financial Risk with the Aid of Hedging Tools
di: Jaroslav Slepecky
Pubblicazione: (2002-12-01)

BROMODOMAIN INHIBITORS REDUCE TH17-TYPE RESPONSES IN SPONDYLOARTHRITIS IN VITRO
di: Hammitzsch, A, et al.
Pubblicazione: (2014)

Synthesis and biological investigation of (+)-JD1, an organometallic BET bromodomain inhibitor
di: Hassell-Hart, S, et al.
Pubblicazione: (2019)

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
di: Noah R. Flynn, et al.
Pubblicazione: (2021-06-01)

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
di: Sergey Karakashev, et al.
Pubblicazione: (2017-12-01)

Chemical tools to probe the role of bromodomains in the parasite Trypanosoma cruzi
di: Laurin, CMC
Pubblicazione: (2019)

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
di: Alison M. Kurimchak, et al.
Pubblicazione: (2016-08-01)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
di: Picaud, S, et al.
Pubblicazione: (2013)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
di: Picaud, S, et al.
Pubblicazione: (2013)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
di: Filippakopoulos, P, et al.
Pubblicazione: (2012)

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
di: Shu, Shaokun, et al.
Pubblicazione: (2017)

Cracking the histone code: Developing inhibitors of bromodomain-acetyl-lysine interactions
di: Conway, S
Pubblicazione: (2013)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
di: Filippakopoulos, P, et al.
Pubblicazione: (2012)

The design and synthesis of 5-and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains
di: Hay, D, et al.
Pubblicazione: (2013)

Effect of BET missense mutations on bromodomain function, inhibitor binding and stability
di: Lori, L, et al.
Pubblicazione: (2016)

Bromodomain inhibitor treatment leads to overexpression of multiple kinases in cancer cells
di: Darshan S. Chandrashekar, et al.
Pubblicazione: (2024-11-01)